Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Sep 10 · below the Ichimoku cloud · RSI 36 · MACD below its signal · 3% above its 52-week low
| 21.50 | 52-week high | +61.90% |
| 17.40 | Previous month high | +31.02% |
| 14.78 | R3 (classic) | +11.32% |
| 14.47 | Previous week high | +8.96% |
| 14.35 | R2 (classic) | +8.03% |
| 14.24 | Previous month low | +7.23% |
| 13.91 | Previous day high | +4.74% |
| 13.81 | R1 (classic) | +4.02% |
| 13.38 | Pivot | +0.73% |
| 13.28 | Price now | |
| 12.94 | Previous day low | −2.56% |
| 12.94 | Previous week low | −2.56% |
| 12.94 | 52-week low | −2.56% |
| 12.84 | S1 (classic) | −3.29% |
| 12.41 | S2 (classic) | −6.58% |
| 11.87 | S3 (classic) | −10.59% |
None of the 29 investors followed here reported a position in MESO in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a MESO trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for MESO.
TimeframesDown on the hourly, daily and weekly, mixed on the monthly.
under a falling 21 EMA, 21 under 50
under a falling 21 EMA, 21 under 50
under a falling 21 EMA, 21 under 50
pulling back under the 21 EMA
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -4.4 | -8.1 | -3.0 | 1.9 | -1.7 | -12.1 | 4.7 | 18.3 | -12.6 | -9.4 | −26.4% | ||
| 2025 | 1.7 | -14.8 | -27.2 | -8.7 | -6.7 | 2.3 | 40.1 | -9.4 | 16.5 | 3.4 | 3.4 | 4.7 | −8.9% |
| 2024 | -20.0 | 11.9 | 154.3 | 31.7 | 12.7 | -8.5 | -0.6 | -0.4 | 21.2 | 2.6 | 39.5 | 69.4 | +800.0% |
| 2023 | 13.4 | 0.0 | -0.3 | -10.3 | 14.6 | 15.7 | 2.3 | -59.7 | -23.6 | -0.8 | 11.5 | -19.1 | −62.2% |
| 2022 | -15.8 | -3.7 | 8.5 | -13.0 | -4.4 | -36.8 | 50.5 | -11.4 | -13.9 | 14.1 | 27.1 | -21.4 | −39.4% |
| 2021 | 5.9 | 6.8 | -13.9 | -7.4 | 0.9 | -3.2 | -6.4 | -6.7 | -8.0 | 0.7 | 0.0 | -20.7 | −43.5% |
| 2020 | 30.1 | -26.0 | -38.3 | 154.3 | 15.2 | -11.2 | 17.8 | 44.3 | -4.0 | -42.4 | 41.0 | -43.7 | +15.2% |
| 2019 | 7.0 | -0.7 | 19.9 | 12.0 | -19.2 | 11.8 | -3.0 | -4.5 | 40.9 | -10.7 | 1.1 | 17.7 | +78.9% |
| 2018 | -7.4 | 34.2 | -20.4 | -4.8 | 3.3 | -3.2 | 29.1 | -14.4 | 34.2 | -13.6 | -31.1 | -15.2 | −29.5% |
| 2017 | 9.7 | 12.3 | 36.3 | 32.7 | -32.9 | -0.6 | -12.5 | -15.1 | -7.3 | -5.1 | 0.4 | 11.9 | +9.2% |
| 2016 | -15.1 | 21.1 | 47.1 | -17.2 | -11.3 | -44.0 | 3.5 | 22.2 | -14.0 | 2.6 | 2.3 | 18.4 | −15.9% |
| 2015 | -12.6 | 4.3 | -15.1 | 6.9 | 3.7 | -6.4 | 3.3 | -16.7 | -7.9 | 9.1 | -50.4 | 3.9 | −64.2% |
| 2014 | -3.4 | 0.5 | -0.8 | -14.6 | 3.6 | -4.0 | -10.1 | 20.7 | -18.5 | -2.1 | -5.8 | 1.0 | −32.7% |
| 2013 | 9.5 | 11.8 | 2.5 | -11.7 | -4.8 | -15.9 | 8.3 | -7.9 | 8.9 | 19.0 | -11.3 | -5.8 | −4.1% |
| 2012 | -3.7 | 21.6 | -0.5 | -3.9 | -18.6 | -7.4 | 11.7 | -1.8 | 7.3 | -14.1 | 4.3 | -12.4 | −21.9% |
| 2011 | 20.8 | -7.6 | 40.4 | 20.6 | -5.1 | 8.2 | 6.7 | -13.0 | -9.4 | 16.8 | -20.8 | -2.4 | +47.2% |
| 2010 | -12.8 | 0.0 | 7.1 | -17.6 | 3.3 | 6.5 | 0.0 | 50.9 | -7.1 | 44.6 | 43.1 | +145.3% |
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Ryoncil for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, Duchenne muscular dystrophy, and biologic refractory inflammatory bowel disease, as well as ulcerative colitis and Crohn's disease; Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease; and Revascor for the treatment of hypoplastic left heart syndrome. The company is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; MPC-150-IM for the treatment or prevention of chronic heart failure; Ryoncil for the treatment of pediatric SR-aGVHD; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM; Grünenthal GmbH to develop and commercialize MPC-06-ID for the treatment of chronic low back pain due to degenerative disc disease in patients; and JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.
Buy / hold / sell counts